US20190314379A1 – October 17, 2019 – METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT

Please complete the required fields.




Inventors :

Andrea Grace HOHMANN; Ken Paul MACKIE; Xiaoyan LIN; Amey S. DHOPESHWARKAR

Owner :

INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Application Number :

US16256787

Document Number :

US20190314379A1

Priority Date :

January 24, 2019

Filing Date :

January 24, 2019

Date of Grant/ Publication :

October 17, 2019

Class :

A61K31 / 52; A61K31 / 366; A61K31 / 485; A61P25 / 04; A61P25 / 36

Abstract

The present disclosure relates to methods of using cannabinoid CB 2 receptor agonist compositions to suppress pain (e.g., neuropathic pain), opioid tolerance, and/or opioid-induced physical dependence in a subject.

Claim(s)

claim 1: 1 . A method of suppressing neuropathic pain without producing tolerance in a subject, the method comprising: a) administering a pharmaceutical composition comprising a cannabinoid CB2 receptor agonist compound to the subject, b) activating one or more G-protein signaling pathways that is sufficient to affect neuropathic pain in the subject, c) improving one or more clinical manifestations of the neuropathic pain in the subject, and d) suppressing the neuropathic pain in the subject.;
claim 2: 10 . A method of reducing or preventing opioid withdrawal in a subject, the method comprising: a) administering to the subject a pharmaceutical composition comprising a LY2828360 compound, an AM1710 compound, or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof, b) activating one or more G-protein signaling pathways that affects opioid withdrawal in the subject, c) suppressing the one or more clinical manifestations of the opioid withdrawal in the subject, and d) reducing or preventing opioid withdrawal in the subject.;
claim 3: 16 . A method of reducing or preventing the development of opioid tolerance in a subject, the method comprising: a) co-administering to the subject one or more pharmaceutical compositions comprising; i) a LY2828360 compound, an AM1710 compound, or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof, and ii) an opioid; b) activating one or more G-protein signaling pathways that effects opioid tolerance in the subject, c) suppressing the development or presentation of one or more clinical manifestations of the opioid tolerance in the subject, and d) reducing or preventing the development of opioid tolerance in the subject.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login